Novo Nordisk (NVO) says its obesity drug Ozempic improved walking distance for diabetes patients with peripheral artery ...

Lexicon Pharmaceuticals Inc. said March 28 it will exclusively license its drug candidate LX9851 to Danish pharmaceutical ...

Developers of cardiology drugs and devices will be back in the spotlight this weekend when the annual scientific meeting of ...

The results pave the way for Rybelsus to become a new treatment option for people living with diabetes and established heart ...

In the latest trading session, Novo Nordisk (NVO) closed at $69.30, marking a -1.23% move from the previous day.

We recently compiled a list of the 12 Best ADR Stocks to Buy According to Hedge Funds. In this article, we are going to take ...

Novo Nordisk shares are experiencing a significant decline amidst intensified investor concerns over its competitiveness in ...

Danish biotech giant Novo Nordisk is trading at an extremely attractive valuation — particularly relative to its main rival, ...

Novo Nordisk is licensing Lexicon Pharmaceuticals' experimental obesity drug in a deal worth up to $1 billion, the Danish ...

Lexicon Pharmaceuticals shares jumped nearly 75% in early trading Friday after the biopharmaceutical company inked a license agreement potentially worth $1 billion with Danish drug maker Novo Nordisk.

Novo Nordisk has entered into an exclusive license agreement with Lexicon Pharmaceuticals Inc. for LX9851, a first-in-class, ...

BofA analysts expect Novo Nordisk’s first-quarter sales to reach 77 billion Danish kroner (DKK), a 17% year-over-year ...